Vitamin B12 is one of those silent MVPs in your body
At 1.7 mg, the GLP-1 receptor activation is near its peak
LEADER 1 A phase 3b, multicenter, international, randomized, double-blind, placebo-controlled study to assess the cardiovascular safety of Victoza
These adverse effects are consistent with those observed in other GLP-1 receptor agonist treatments
Findings: RCTSTEP 3 Trial - Wegovy vs Placebo for Weight Loss in Overweight Adults Without DM, JAMA (2021) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=611 | length = 68 weeks) in overweight or obese adults (average weight 233 lbs | average BMI 38) without diabetes Treatment: Wegovy 2.4 mg sub-q once weekly vs Placebo
Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial (September 2017) Doi: Lisdexamfetamine Dimesylate (Vyvanse), A Prodrug Stimulant for Attention-Deficit/Hyperactivity Disorder (May 2010) Doi: The Influence of Depressive Symptoms on Executive Functioning in Binge Eating Disorder: A Comparison of Patients and Non-Obese Healthy Controls (April 2019) Doi: Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review (August 05, 2021) Doi: SSRI Antidepressant Medications: Adverse Effects and Tolerability (February 01, 2001) Doi: Treatment of Obese Patients With Binge Eating Disorder Using Topiramate: A Review (July 07, 2009) Doi: Successful Treatment of Binge Eating Disorder With the GLP-1 Agonist Semaglutide: A Retrospective Cohort Study (August 08, 2023) Doi:
